Recurrent Small Cell Lung Cancer (SCLC) Recruiting Phase 1 / 2 Trials for Ipilimumab (DB06186)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04610658Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCTreatment